Treatment of acute mixed-cell leukemia with autologous hematopoietic SCT followed by allogeneic hematopoietic stem cell micro-transplantation

[1]  Xiuli Wu,et al.  Allo-HSCT for acute leukemia of ambiguous lineage in adults: the comparison between standard conditioning and intensified conditioning regimens , 2013, Annals of Hematology.

[2]  H. Ai,et al.  HLA-mismatched stem-cell microtransplantation as postremission therapy for acute myeloid leukemia: long-term follow-up. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  H. Drexler,et al.  Clinical, immunophenotypic, cytogenetic, and molecular genetic features in 117 adult patients with mixed-phenotype acute leukemia defined by WHO-2008 classification , 2012, Haematologica.

[4]  J. Schwarz,et al.  Estimation of molecular upper remission limit for monitoring minimal residual disease in peripheral blood of acute myeloid leukemia patients by WT1 expression. , 2012, Experimental and therapeutic medicine.

[5]  H. Ai,et al.  Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients. , 2011, Blood.

[6]  Jianmin Yang,et al.  Clinical and biological characteristics of adult biphenotypic acute leukemia in comparison with that of acute myeloid leukemia and acute lymphoblastic leukemia: a case series of a Chinese population , 2009, Haematologica.

[7]  R. Slany.  The molecular biology of mixed lineage leukemia , 2009, Haematologica.

[8]  J. Connors,et al.  Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.